1 – 10 of 15
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Next-generation CD40 agonists for cancer immunotherapy
(
- Contribution to journal › Scientific review
- 2023
-
Mark
Myeloid CD40 deficiency reduces atherosclerosis by impairing macrophages’ transition into a pro-inflammatory state
(
- Contribution to journal › Article
-
Mark
Early Pharmacodynamic Changes Measured Using RNA Sequencing of Peripheral Blood from Patients in a Phase I Study with Mitazalimab, a Potent CD40 Agonistic Monoclonal Antibody
(
- Contribution to journal › Article
- 2021
-
Mark
Soluble CD40 levels in plasma are associated with cardiovascular disease and in carotid plaques with a vulnerable phenotype
(
- Contribution to journal › Article
-
Mark
Rationale and clinical development of CD40 agonistic antibodies for cancer immunotherapy
(
- Contribution to journal › Scientific review
- 2015
-
Mark
Kick-starting the cancer-immunity cycle by targeting CD40
(
- Contribution to journal › Debate/Note/Editorial
- 2012
-
Mark
Gene expression profiling indicates that immunohistochemical expression of CD40 is a marker of an inflammatory reaction in the tumor stroma of diffuse large B-cell lymphoma
(
- Contribution to journal › Article
- 2007
-
Mark
Diffuse large B-cell lymphoma - tumour characteristics on RNA and protein level associated with prognosis
2007)(
- Thesis › Doctoral thesis (compilation)
-
Mark
CD40 expression identifies a prognostically favourable subgroup of diffuse large B-cell lymphoma.
(
- Contribution to journal › Article
- 2002
-
Mark
The CD40 Receptor - Target,Tool and Technology
2002)(
- Thesis › Doctoral thesis (compilation)